Lin Yang

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 232 citations · Full text

Medicine, Oncology, Radiation Oncology +14

TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response

Zexian Zeng, Cheryl J. Wong, Lin Yang et al. · Nucleic Acids Research · 2021 · 132 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression

Guanghai Yang, Lin Yang, Wendong Wang et al. · Gene · 2015 · 122 citations

Medicine, Molecular Biology, Molecular Medicine +12

scMAGeCK links genotypes with multiple phenotypes in single-cell CRISPR screens

Lin Yang, Yuqing Zhu, Hua Yu et al. · Genome biology · 2020 · 97 citations · Full text

Life Sciences, Bioinformatics, Genetics +17

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Livius Penter, Yang Liu, Jacquelyn O. Wolff et al. · Blood · 2023 · 50 citations · Full text

Medicine, Immunology, Oncology +17